Double-blind study on SY 5555 in bacterial pneumonia

Atsushi Saito, Hiroshi Fukuhara, Jun Inadome, Yuei Irabu, Katsuyoshi Shimoji, Akira Saito, Masumi Tomizawa, Yohmei Hiraga, Mitsuhide Ohmichi, Kyuichiro Sekine, Hirotsugu Takabatake, Susumu Ito, Kohki Kikuchi, Asako Yamamoto, Hiroshi Miura, Hirokazu Kurokawa, Mitsunobu Honma, Shinichi Miura, Akihiko Onodera, Kazuki KonishiMasashi Tamura, Kenichi Takeuchi, Akira Watanabe, Toshihiro Nukiwa, Takashi Matsuda, Hideo Arai, Kazunao Niizuma, Yasuo Tanno, Kunio Shirato, Masahiro Sakamoto, Masataka Katsu, Akira Ohishi, Masaru Shibata, Yoshio Uzuka, Kaoru Shimada, Shinichi Oka, Yasuyuki Sano, Yasufumi Miyamoto, Yasuo Arai, Kohya Shiba, Masaki Yoshida, Osamu Sakai, Hiroichi Tanimoto, Kazuo Ohara, Tetsuo Okamura, Atsushi Saito, Koichiro Nakata, Koji Narui, Masaru Koyama, Hiroyuki Kobayashi, Shin Kawai, Koichiro Kudo, Haruhito Sugiyama, Harumi Shishido, Hideaki Nagai, Shoichiro Irimajiri, Yasuo Matsuoka, Eiji Ohki, Jingoro Shimada, Seiji Hori, Takeshi Azuma, Shigeki Momose, Moromichi Sakata, Kazuhiko Someya, Satoru Takahashi, Yoshiaki Nagayama, Kohjiro Sekita, Masamitsu Takahashi, Masahiko Namiki, Akitoshi Ishizaka, Fumio Matsumoto, Takeo Imai, Shigeki Odagiri, Hiroshi Takahashi, Koshiro Watanabe, Hideo Kunigashira, Koichi Wada, Masaaki Arakawa, Shigeyuki Hoshino, Hiroki Tsukada, Fumihide Iwata, Nobuki Aoki, Yasutoshi Suzuki, Osamu Sekine, Atsuhiko Sato, Kingo Chida, Keishi Hayakawa, Shiro Imokawa, Takeshi Yagi, Hideki Suganuma, Masami Taniguchi, Masatoshi Iwata, Masaaki Ida, Tomoko Kita, Yutaka Nakano, Izumi Shichi, Sumihito Morita, Sumio Kawakatsu, Kazumasa Yasuda, Niichiro Akiyama, Shigeo Takizawa, Mikae Nakamura, Kaoru Shimokata, Satoshi Ichiyama, Yukio Ogura, Takuya Miyachi, Shuzo Sakai, Hironobu Minami, Masashi Yamamoto, Eishi Takagi, Naoko Yurikusa, Takanao Murate, Joji Ohno, Kazuyoshi Imaizumi, Yasunobu Totani, Hidetaka Kawatsu, Haruyo Miyaji, Toshihiko Takeuchi, Yasuo Yamada, Kazuhide Yamamoto, Ikuji Usami, Toshiyuki Yamamoto, Kanzo Suzuki, Toru Matsuura, Kojiro Yasunaga, Seibun Yonezu, Yoshitaka Yamanaka, Fumio Miki, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Rinzo Soejima, Yoshihito Niki, Niro Okimoto, Toshiharu Matsushima, Makoto Kimura, Michio Yamakido, Jyun Inamizu, Teruomi Miyazawa, Masao Kuwabara, Kenichi Arita, Kazuhiro Daido, Takao Sasaki, Yukio Matsumoto, Yuji Sugimoto, Nobuo Ueda, Masahiro Kitade, Minoru Yoshida, Masayuki Nakanishi, Hideo Toyoshima, Kotaro Oizumi, Takafumi Yano, Fumio Tanaka, Yoshiyuki Mitsutake, Masashi Kawahara, Shinzo Kawaguchi, Masazumi Saisho, Hironari Shigematsu, Tsuneo Ishibashi, Masahiro Takamoto, Akira Kajiki, Akihito Ikeda, Hozumi Yamada, Osamu Kato, Shigetaka Kuroki, Masaya Yamaguchi, Kohei Hara, Shigeru Kohno, Hironobu Koga, Kazunori Tomono, Mitsuo Kaku, Koichi Watanabe, Yasumasa Dotsu, Hideo Mashimoto, Yuichi Inoue, Takakazu Ohtsubo, Tsuyoshi Fujii, Sumio Kawamura, Keizo Matsumoto, Moritoshi Akiyama, Akitaka Iwagaki, Kazunori Ohishi, Masakazu Takasugi, Masaru Nasu, Yoichiro Goto, Tohru Yamasaki, Hiroyuki Nagai, Jun Goto, Kazuo Kitagawa, Hiroshi Nagaoka, Masayuki Ando, Moritaka Suga, Kazuto Yamasaki, Yasutsugu Fukuda, Katsumasa Tokunaga, Yoshihisa Nakagawa, Kazuyasu Shimazu, Hiroyuki Muranaka, Jiro Tamiya, Tetsunobu Sakata, Yoshikatsu Go, Yuriko Nishiura, Kiyoshi Shima, Shinobu Takenaka, Mitsuyoshi Nakashima, Keizo Yamaguchi, Yoichi Hirakata, Fusako Kashitani

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

To evaluate the clinical usefulness of SY 5555, a new oral penem, in the treatment of bacterial pneumonia, a double-blind comparative study, using cefotiam hexetil (CTM-HE) as the control drug, was conducted in various clinical institutes. The drugs were given at a daily dose of 900 mg of SY 5555 or 600 mg of CTM-HE, divided three times a day, for 14 days. 1. The clinical efficacy rates were 90.2% (83/92) for the SY 5555 group and 85.1% (86/101) for the CTM-HE group. The efficacy rates of the two drugs were not significantly different. 2. Bacteriologically, the eradication rates were 77.4%(24/31) for the SY 5555 group and 89.2% (33/37) for the CTM-HE group, showing no statisticaly significant difference between them. 3. Side effects were observed 8 of 111 patients in the SY 5555 group and 7 of 111 patients in the CTM-HE group. The main side effect was gastrointestinal symptoms in both groups. 4. The incidence of abnormal changes in laboratory findings was 19.6% (21/107) in the SY 5555 group and 16.8% (18/107) in the CTM-HE group. 5. The total usefulness rates were 88.3% (83/94) in the SY 5555 group and 81.4% (83/102) in the CTM-HE group. There was no significant difference between the two groups. The above results showed that in terms of efficacy and safety the SY 5555 group was equal to the CTM-HE group. SY 5555 was concluded to be a useful drug for the treatment of bacterial pneumonia.

Original languageEnglish
Pages (from-to)616-638
Number of pages23
JournalCHEMOTHERAPY
Volume42
Issue number5
DOIs
Publication statusPublished - 1994

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'Double-blind study on SY 5555 in bacterial pneumonia'. Together they form a unique fingerprint.

  • Cite this

    Saito, A., Fukuhara, H., Inadome, J., Irabu, Y., Shimoji, K., Saito, A., Tomizawa, M., Hiraga, Y., Ohmichi, M., Sekine, K., Takabatake, H., Ito, S., Kikuchi, K., Yamamoto, A., Miura, H., Kurokawa, H., Honma, M., Miura, S., Onodera, A., ... Kashitani, F. (1994). Double-blind study on SY 5555 in bacterial pneumonia. CHEMOTHERAPY, 42(5), 616-638. https://doi.org/10.11250/chemotherapy1953.42.616